Ultragenyx Sells Second Priority Review Voucher for $203M, Adding Non-Dilutive Cash
RARE sits 20% above its 52-week low of $12.73.
Summary
Ultragenyx agreed to sell its Rare Pediatric Disease Priority Review Voucher, received with the FDA approval of FAYUVI for Sanfilippo syndrome type A, for $203 million. This is the company's second PRV sale in a week, following the $210 million GENGLYCOS voucher sale announced October 7. The combined $413 million in non-dilutive funding strengthens the balance sheet and supports the path to profitability. The transaction is subject to HSR clearance and customary closing conditions.
Updates
· SEC 8-K — The 8-K confirms the $203 million PRV sale agreement dated October 8, 2026, with payment in cash upon closing and subject to HSR clearance.
At the time of this announcement, RARE was trading at $15.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.73 to $39.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.